Abdominal Ultrasound With Doppler and Peripheral Hemogram in Assesment Inflammatory Bowel Disease

assessment of inflammatory bowel disease patients in activity and remission by abdominal ultrasound examine non-invasive and in physiological condition by measuring the colon wall thickness in diagnosis and follow up the patient also including extra intestinal features such as the splanchnic vessels,mesentery and lymph nodes . Doppler u.s can evaluate bowel wall vascularity In activity and remission . peripheral hemogram in relationship to activity inflammatory bowel disease asses anemia ,increase monocyte and decrease mean platelet volume( MPV) . also,the investigator will evaluate the outcome of different lines of treatment traditional and biologic therapy (response to treatment,times of activity and complications)

Study Overview

• Status: Completed
• Conditions: Inflammatory Bowel Diseases
• Intervention / Treatment: Drug: Infliximab

Detailed Description

the participants will follow up the patient for 1 year in the first visit

All patients in this study will be subjected to:

1. Detailed history.
2. Careful physical examination

3. laboratory investigation

   1. complete blood picture.
   2. liver function
   3. kidney function
   4. Iron profile(serum iron ,serum ferritin
   5. ESR (erythrocyte sedimentation rate )

   g-CRP (C reactive protein) f-LDH (lactate dehydrogenase)

4. Abdominal us(the colon wall thickness,lymph nodes,mass,other organs)
5. Doppler us (mesenteric vessels)
6. colonoscopy after 1 year of treatment follow up every 3 months by abdominal US and peripheral hemogram and last visit after 1 year colonoscopy and biopsy for assessment response to treatment

• Study Type: Observational
• Enrollment (Actual): 60

Contacts and Locations

Study Locations

• Egypt
  • Assiut, Egypt
    • Hyam Fathy

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 15 years to 60 years (Child, Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

all patients diagnosed inflammatory bowel disease (ulcerative colitis and crohns disease) at age(15 -60)

Description

Inclusion Criteria

• patients diagnosed ulcerative colitis at age(15-60)
• patients diagnosed crohns disease at age(15-60)k

Exclusion criteria

• liver cirrhosis and portal hypertension
• spontaneous bacterial peritonitis
• Ischemic colitis

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
patient on traditional therapy; Drug: steroid,5ASA , immuran for assesment the outcome of therapy in inflammatory bowel disease steroid(40- 60mg tablet),5ASA(pentasa 3-4gm tablet),azathioprin (immuran 100 mg tablet)	Drug: Infliximab; follow up the patients who received this drugs for 1 year by abdominal ultrasound,peripheral hemogram and colonoscopy; Other Names: steroid,immuran 5ASA
patient on infliximab; drug : infliximab (5mglkg intravenous)for the first dose,the second dose after 2 weeks the third dose after 6 weeks then every 2 months	Drug: Infliximab; follow up the patients who received this drugs for 1 year by abdominal ultrasound,peripheral hemogram and colonoscopy; Other Names: steroid,immuran 5ASA

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
the role abdominal ultrasound in assessment inflammatory bowel disease	measure the thickness of the colon by abdominal ultrasound and doppler mesenteric vessels .more than 4ml detect activity doppler mesenteric highly vascularity in activity	2 year

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Assesment inflammatory bowel disease by complete blood picture	follow up haemoglobin level (less than 10 mg) indicate anemia which mean the patient uncontrolled monocyte( monocyte more than 12% of white blood cell count detect activity) Mean platelet volume less than 6 fl which decrease in activity inflammatory bowel disease	2year

Collaborators and Investigators

• Sponsor: Assiut University
• Investigators: Study Director: ahmed ashmawy, Lecturer of Internal Medicine

Study record dates

Study Major Dates

• Study Start (Actual): July 1, 2018
• Primary Completion (Actual): February 1, 2021
• Study Completion (Actual): October 1, 2021

Study Registration Dates

• First Submitted: January 9, 2018
• First Submitted That Met QC Criteria: February 20, 2018
• First Posted (Actual): February 26, 2018

Study Record Updates

• Last Update Posted (Actual): August 29, 2023
• Last Update Submitted That Met QC Criteria: August 26, 2023
• Last Verified: July 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; Gastrointestinal Diseases; Gastroenteritis; Inflammatory Bowel Diseases; Intestinal Diseases; Anti-Inflammatory Agents; Antirheumatic Agents; Gastrointestinal Agents; Dermatologic Agents; Tumor Necrosis Factor Inhibitors; Infliximab
• Other Study ID Numbers: assiut hospitals university